Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to tackle two key risks in kidney dialysis patients

NCT ID NCT00542386

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated Jun 22, 2026 · Updated 28 times

Summary

This Phase 3 trial tested MCI-196, a drug that binds phosphorus and lowers cholesterol, in 642 adults on dialysis with chronic kidney disease. Participants received either MCI-196 or a placebo for 12 weeks. The goal was to see if the drug could safely reduce both serum phosphorus and LDL-cholesterol levels, which are linked to heart and bone problems in dialysis patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Study site

    Ajka, Hungary

  • Study site

    Baja, Hungary

  • Study site

    Budapest, Hungary

  • Study site

    Esztergom, Hungary

  • Study site

    Győr, Hungary

  • Study site

    Hatvan, Hungary

  • Study site

    Kisvárda, Hungary

  • Study site

    Lecco, Italy

  • Study site

    Modena, Italy

  • Study site

    Pavia, Italy

  • Study site

    Roma, Italy

  • Study site

    Alor Star, Malaysia

  • Study site

    Ipoh, Malaysia

  • Study site

    Kajang, Malaysia

  • Study site

    Klang, Malaysia

  • Study site

    Kota Kinabalu, Malaysia

  • Study site

    Kuala Terengganu, Malaysia

  • Study site

    Kuantan, Malaysia

  • Study site

    Kuching, Malaysia

  • Study site

    Malacca, Malaysia

  • Study site

    Seremban, Malaysia

  • Study site

    Taiping, Malaysia

  • Study site

    Skopje, North Macedonia

  • Study site

    Lodz, Poland

  • Study site

    Poznan, Poland

  • Study site

    Płock, Poland

  • Study site

    Rybnik, Poland

  • Study site

    Warsaw, Poland

  • Study site

    Wroclaw, Poland

  • Study site

    Zielona Góra, Poland

  • Study site

    Arkhangelsk, Russia

  • Study site

    Armavir, Russia

  • Study site

    Chelyabinsk, Russia

  • Study site

    Chita, Russia

  • Study site

    Irkutsk, Russia

  • Study site

    Ivanovo, Russia

  • Study site

    Kaluga, Russia

  • Study site

    Kemerovo, Russia

  • Study site

    Khabarovsk, Russia

  • Study site

    Krasnodar, Russia

  • Study site

    Krasnoyarsk, Russia

  • Study site

    Moscow, Russia

  • Study site

    Nizhny Novgorod, Russia

  • Study site

    Novokuznetsk, Russia

  • Study site

    Novorossiysk, Russia

  • Study site

    Novosibirsk, Russia

  • Study site

    Omsk, Russia

  • Study site

    Petrozavodsk, Russia

  • Study site

    Rostov-on-Don, Russia

  • Study site

    Saint Petersburg, Russia

  • Study site

    Smolensk, Russia

  • Study site

    Tomsk, Russia

  • Study site

    Tver', Russia

  • Study site

    Tyumen, Russia

  • Study site

    Vladimir, Russia

  • Study site

    Vladivostok, Russia

  • Study site

    Volzhskiy, Russia

  • Study site

    Yaroslavl, Russia

  • Study site

    Yekaterinburg, Russia

  • Study site

    Belgrade, Serbia

  • Study site

    Kragujevac, Serbia

  • Study site

    Niš, Serbia

  • Study site

    Novi Sad, Serbia

  • Study site

    Chernivtsi, Ukraine

  • Study site

    Dnipro, Ukraine

  • Study site

    Ivano-Frankivsk, Ukraine

  • Study site

    Kharkiv, Ukraine

  • Study site

    Kiev, Ukraine

  • Study site

    Mykolaiv, Ukraine

  • Study site

    Ternopil, Ukraine

  • Study site

    Uzhhorod, Ukraine

  • Study site

    Zaporizhya, Ukraine

  • Study site

    Zhytomyr, Ukraine

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

MCI-196 (colestilan)

What this could lead to

If it works, this could provide a new option to manage high phosphorus and cholesterol in dialysis patients, potentially reducing heart and bone complications.

What could go wrong

This is a completed Phase 3 trial, but results may not show significant benefit over placebo. Side effects are possible, and the drug may not be approved or widely adopted.

Conditions

The condition(s) this trial relates to.

chronic renal failure syndrome Dyslipidemias hyperphosphatemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE DIALYSIS DYSLIPIDEMIA HYPERPHOSPHATEMIA